drugset / Trial / NCT01406704

Effects of Rosiglitazone and Alpha-lipoic Acid on the Patients With Pathologically Proved NASH

NCT01406704

Phase 4 Terminated 26 enrolled Seoul St. Mary's Hospital GlaxoSmithKline · collab
RandomizedParallel-groupSingle-blindPrevention

Summary

This study is to evaluate the effects of Rosiglitazone, insulin sensitizer and alpha-lipoic acid, antioxidant on patients with pathologically proved NASH (non-alcoholic steato-hepatitis).

Timeline

Start
2004-01
Primary completion
2010-12
Completion
2013-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Rosiglitazone Small molecule 8 mg
Subject alpha-lipoic acid Small molecule 1800 mg